Business
Moderna Announces Additional Supply for Q2 2022 of Vaccine for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries
Q2 deliveries almost double – a further 56.5 million in options exercised by COVAX, for a total 116.5 million doses for delivery in the second quarter of
About this update from Moderna, Inc.
[{"type":"text","content":"\nQ2 deliveries almost double – a further 56.5 million in options exercised by COVAX, for a total 116.5 million doses for delivery in the second quarter of 2022\n\nPer the original APA, COVAX Facility retains options for up to 233 million additional doses in 2022\n\nDoses provided at lowest tiered price, in keeping with Moderna’s global access principles commitment\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nModerna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement with Gavi, the Vaccine Alliance to supply up 116.5 million doses of Moderna’s COVID-19 vaccine to be delivered in the second quarter of 2022. The exercise of these options for additional doses represents an increase from an earlier agreement for 60 million doses of Moderna’s COVID-19 vaccine that was communicated earlier this year. As per the advance purchase agreement signed on behalf of the COVAX Facility, Gavi continues to retain the option to procure 233 million additional doses in 2022 for a potential total of 500 million doses between 2021 and 2022 under the agreement. All doses are offered at Moderna’s lowest tiered price, in line with the Company’s global access commitments.\n\nThis agreement covers the 92 Gavi COVAX Advance Market Commitment (AMC) low- and middle-income countries. COVAX is a global initiative co-led by Gavi, the Vaccine Alliance (Gavi), the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO), to ensure equitable access to COVID-19 vaccines for all countries, regardless of income levels.\n\n“I am grateful to our partners at Gavi and COVAX for their work and collaboration to reach this agreement. This is another important milestone as we work to ensure that people around the world have access to our COVID-19 vaccine,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We support COVAX’s mission to ensure broad, affordable and equitable access to COVID-19 vaccines and we remain committed to doing everything that we can to ending this ongoing pandemic with our mRNA COVID-19 vaccine. We have recently offered to COVAX to access more vaccines for Q2 and Q3 2022.”\n\nAbout Moderna\n\nIn 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger...